These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34145693)

  • 1. Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time.
    Stonebraker JS; O'Mahony B; Noone D; Iorio A
    Haemophilia; 2021 Sep; 27(5):e596-e608. PubMed ID: 34145693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres.
    Stonebraker JS; Ducore JM
    Haemophilia; 2021 Jan; 27(1):e22-e29. PubMed ID: 33012106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B.
    Chhabra A; Spurden D; Fogarty PF; Tortella BJ; Rubinstein E; Harris S; Pleil AM; Mellor J; de Courcy J; Alvir J
    Blood Coagul Fibrinolysis; 2020 Apr; 31(3):186-192. PubMed ID: 32271314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
    J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.
    Yu JK; Wong WWL; Keepanasseril A; Iorio A; Edginton AN
    Haemophilia; 2023 Mar; 29(2):488-497. PubMed ID: 36528890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of extended half-life factor VIII in children with severe haemophilia A.
    Dettoraki A; Michalopoulou A; Mazarakis M; Saslis S; Stamati I; Kapsimali Z; Pergantou H
    Haemophilia; 2022 Jul; 28(4):619-624. PubMed ID: 35503081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Analysis of Dispensed International Units of Coagulation Factor VIII and Resultant Expenditures for Hemophilia A Patients: A Comparison Between Standard Half-Life and Extended Half-Life Products.
    Chhabra A; Fogarty PF; Tortella BJ; Spurden D; Alvir J; McDonald M; Hodge J; Pleil AM
    Manag Care; 2018 Oct; 27(10):39-50. PubMed ID: 30309448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis for hemophilia A without inhibitors: treatment options and considerations.
    Valentino LA; Khair K
    Expert Rev Hematol; 2020 Jul; 13(7):731-743. PubMed ID: 32573295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B.
    Rampotas A; Desborough MJR; Raza-Burton S; Taylor S; Wilkinson A; Hall GW; Shapiro S; Curry N
    Haemophilia; 2020 Mar; 26(2):278-281. PubMed ID: 32083769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and outcomes of low-dose and low-frequency prophylaxis with recombinant extended half-life products (Fc-rFVIII and Fc-rFIX) in Ivorian children with hemophilia: Two-year experience in the setting of World Federation of Haemophilia humanitarian aid programme.
    Lambert C; Meité N; Sanogo I; Lobet S; Hermans C
    Haemophilia; 2021 Jan; 27(1):33-40. PubMed ID: 33245818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain.
    Kim HK; Peral C; Rubio-Rodríguez D; Rubio-Terrés C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):315-320. PubMed ID: 32597317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021.
    Abbattista M; Ciavarella A; Noone D; Peyvandi F
    J Thromb Haemost; 2023 Mar; 21(3):546-552. PubMed ID: 36710195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021.
    Di Minno A; Spadarella G; Esposito S; Mathew P; Di Minno G; Mannucci PM
    Blood Rev; 2021 Nov; 50():100849. PubMed ID: 34024681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Amount of Clotting Factor Concentrates Dispensed and Annual Medical Expenditures for Japanese Patients with Hemophilia B.
    Fukutake K; Togo K; Xu L; Markson LE; Alvir JMJ; Winburn I; Karumori T
    J Blood Med; 2023; 14():649-661. PubMed ID: 38143791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.